Abstract |
Metaiodobenzylguanidine ( mIBG), developed 30 years ago, is taken up by tumours expressing the noradrenaline transporter. Radiolabelled with I-123 or I-131, mIBG has become a gold standard for diagnostic imaging of pediatric and adult neuroendocrine cancer. Within a few years of its clinical introduction, I-131 mIBG was found to be an effective palliative treatment with minimal toxicity that in some cases could produce a complete response. The importance of internal dosimetry for I-131 mIBG therapy has been demonstrated by a number of studies showing that absorbed doses delivered to tumours and organs-at-risk from standard and weight-based activities can vary by an order of magnitude. However, significant correlations between the whole-body absorbed dose and myelotoxicity have been demonstrated and studies based on this relationship have enabled treatments to be tailored to the individual. Ongoing developments include patient-specific treatment planning based on tumour dosimetry and cocktails of radionuclides and radiosensitisers.
|
Authors | G D Flux, S J Chittenden, F Saran, M N Gaze |
Journal | The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
(Q J Nucl Med Mol Imaging)
Vol. 55
Issue 2
Pg. 116-25
(Apr 2011)
ISSN: 1824-4785 [Print] Italy |
PMID | 21386786
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Iodine Radioisotopes
- Radiopharmaceuticals
- 3-Iodobenzylguanidine
|
Topics |
- 3-Iodobenzylguanidine
(administration & dosage, therapeutic use)
- Adult
- Child
- Humans
- Iodine Radioisotopes
(administration & dosage, therapeutic use)
- Neuroendocrine Tumors
(diagnostic imaging, radiotherapy)
- Radionuclide Imaging
- Radiopharmaceuticals
(administration & dosage, therapeutic use)
- Radiotherapy Planning, Computer-Assisted
|